MedTrace Logo

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

NCT06071442 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-08-12

No results posted yet for this study

Summary

This study will investigate the potential drug interactions between vemircopan and metformin, rosuvastatin, levonorgestrel/ ethinyl estradiol (LNG/EE)-containing oral contraceptive(s) (OCs), and carbamazepine in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

Vemircopan

Participants will receive oral tablets of Vemircopan.

DRUG

Rosuvastatin

Participants will receive oral coated tablets of Rosuvastatin.

DRUG

Metformin

Participants will receive oral film-coated tablets of Metformin.

DRUG

Levonorgestrel / Ethinyl Estradiol

Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.

DRUG

Carbamazepine

Participants will receive oral chewable tablets of Carbamazepine.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-17
Primary Completion
2024-04-12
Completion
2024-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06071442 on ClinicalTrials.gov